Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
Chinese Market Treatment Ecnoglutide SLIMMER Phase 3 was conducted in Chinese adults and demonstrated strong efficacy (15.4% weight loss at 48 weeks)
About 36% of SURMOUNT-1 participants on 15 mg hit 25% body weight loss by week 72
Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease and is associated with significant cardiovascular morbidity and mortality
Nature Communications, 15, 1223
In the SURMOUNT-1 trial, the highest dose of Tirzepatide produced an average weight loss of 22.5% over 72 weeks the largest seen with any approved weight loss medication in Canada
US$ 27.91
US$ 22.47
US$ 27.67
US$ 22.00
US$ 26.16
US$ 26.16
US$ 28.43
